Matteo Cinquepalmi

Matteo Cinquepalmi

Auto-generated profile, based on publicly available information

Matteo Cinquepalmi

General Surgery Unit, Department of Medical and Surgical Sciences and Translational Medicine, St. Andrea University Hospital, Sapienza University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2016 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
WLWhitney Liddy
Whitney Liddy
SBSamuel R. Barber
Samuel R. Barber
MCMatteo Cinquepalmi
Matteo Cinquepalmi
BLBrian M. Lin
Brian M. Lin
SPStephanie Patricio
Stephanie Patricio
GRGregory Randolph
Gregory Randolph

16 November 2016 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
SBSamuel R. Barber
Samuel R. Barber
WLWhitney Liddy
Whitney Liddy
NKNatalia Kyriazidis
Natalia Kyriazidis
MCMatteo Cinquepalmi
Matteo Cinquepalmi
BLBrian M. Lin
Brian M. Lin
GRGregory W Randolph
Gregory W Randolph

1 September 2018 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
ABAntonio Brescia
Antonio Brescia
MPMassimo Pezzatini
Massimo Pezzatini
GRGherardo Romeo
Gherardo Romeo
MCMatteo Cinquepalmi
Matteo Cinquepalmi
FPFioralba Pindozzi
Fioralba Pindozzi
FLFulger Lazar
Fulger Lazar

5 April 2019 in Anticancer Research
Verified
Journal Article
Open access
PDF file
PAPaolo Aurello
Paolo Aurello
GBGiammauro Berardi
Giammauro Berardi
GMGiovanni Moschetta
Giovanni Moschetta
MCMatteo Cinquepalmi
Matteo Cinquepalmi
LALaura Antolino
Laura Antolino
GRGiovanni Ramacciato
Giovanni Ramacciato
Background: Esophageal cancer is the ninth most common cancer. The only potentially curative treatment is surgical resection, which unfortunately is still associated with major complications, the most important being anastomotic leakage, currently with an overall rate of up to 26% morbidity. The aim of this systematic review was to evaluate the relationship between anastomotic leakage and recurrence of disease. Materials and Methods: A literature search was systematically performed. Seven out of 312 articles dated between 2009 and 2018 fulfilled the selection for a total of 5,433 patients. Results: The frequency of anastomotic leakage ranged from 7.2 to 11.2%. Patients affected by anastomotic leakage had a recurrence rate of 9-56%. Conclusion: Closer follow-up or even more aggressive oncological therapy should be considered for patients affected by anastomotic leakage after surgery for carcinoma of the distal esophagus and gastroesophageal junction.

24 June 2020 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
ALAntolino Laura
Antolino Laura
CACrovetto Anna
Crovetto Anna
MCMatteo Cinquepalmi
Matteo Cinquepalmi
MGMoschetta Giovanni
Moschetta Giovanni
MSMattei Maria Sole
Mattei Maria Sole
RGRamacciato Giovanni
Ramacciato Giovanni

3 February 2020 in Anticancer Research
Verified
Journal Article
Open access
PDF file
PAPaolo Aurello
Paolo Aurello
MCMatteo Cinquepalmi
Matteo Cinquepalmi
NPNiccolò Petrucciani
Niccolò Petrucciani
GMGiovanni Moschetta
Giovanni Moschetta
LALaura Antolino
Laura Antolino
GRGiovanni Ramacciato
Giovanni Ramacciato
Background/Aim: Gastric cancer is the fifth most frequently diagnosed cancer and the second most common cause of cancer-related death. The only potentially curative treatment is surgical resection, which is associated with potentially severe complications, such as anastomotic leakage. The aim of this systematic review was to evaluate the relationship between anastomotic leakage and overall and disease-free survival after surgery for gastric cancer. Materials and Methods: A systematic literature search was performed and 7 articles published between 2010 and 2019 were included, including a total of 7,167 patients. Results: Among the included studies the frequency of anastomotic leakage ranged from 6 to 41%. Patients affected by anastomotic leakage had an overall survival ranging between 4.1 and 97.6 months, whereas patients who did not experience anastomotic leakage had an overall survival between 23 and 109.5 months. Conclusion: Closer follow-up or even more aggressive oncological therapy may be considered for patients affected by anastomotic leakage after surgery for gastric cancer.